We are looking for a consultant will be hired for a period of 6 months to develop the 2nd part of the Aging of KPs study in MENA with the support of the MCoalition team. The consultant will be required to communicate with partners and organizations, set review procedures and consent form, gather and document stories and photos (if available), write the social book (report), review and edit it after the reception of feedback.
The Global fund Trans* toolkit is a simple tool for trans* individuals to understand the dynamics of the global fund and a guide on how to apply and how to become a part and the Global fund network, in order to have the trans- voice heard in the MENA region.
“Mrayti” is the first regional study on the needs of trans* individuals in the MENA region. This study is 100% Trans* led, implemented, collected and analyzed. It is a reflection on the situation of Trans* in the region, and a glimpse of what is happening in this huge area of the world. “Mrayti” also includes a historical review on the situation of Trans* individuals in the region area; it explains the social context and explains why stigma, violence and the alienation of Trans* individuals on social and family levels is prevalent in the MENA region.
Description: What are the different types of Hepatitis?
There are three different types of hepatitis, some of which are spread more easily than others. Hepatitis A, B and C can all be transmitted sexually, however hepatitis B is the type most likely to be sexually transmitted. All types of hepatitis are serious and affect the liver. Hepatitis B and C are the leading cause of liver cancer and are the most common reason for liver transplants.
Transmission: How is Hepatitis transmitted?
|Hepatitis A||Hepatitis B||Hepatitis C|
|– Unprotected Rimming
– Through contaminated food or water
– Unprotected sex
|– Through blood and other body fluids
– Unprotected vaginal, anal or oral sex
– Sharing equipment such as snorting saws and needles
– Tattoos and piercing
|– Through blood and other body fluids
– Unprotected vaginal, anal or oral sex
– Sharing drug equipment
– Tattoos and piercing
Symptoms: what do common signs include?
– Body aches, weakness, tiredness
– Loss of appetite
– Nausea or vomiting
– Diarrhea or constipation
– Dark urine
– Light colored stool
– A dull ache in the right upper side of the abdomen
– Yellow color to the skin called jaundice
– Itchy skin
– Joint pain and rashes
– Some people with hepatitis have no signs.
A blood test will show your doctor what type of hepatitis you have. Your treatment will be based on your type of hepatitis and may include:
- Take only the medicines prescribed by your doctor. Other medicines can affect your liver.
- Do not drink alcohol since it can further damage your liver.
- Do not smoke. Avoid second-hand smoking too.
- Eat small portions of low-fat food to decrease nausea.
- Apply cream often to itchy, dry skin.
Hepatitis A: There’s currently no cure for hepatitis A, but it normally gets better on its own within a couple of months. You can usually look after yourself at home. But it’s still a good idea to have a blood test if you think you could have hepatitis A, as more serious conditions can have similar symptoms.
Hepatitis B: There is no cure for hepatitis B, but supportive care can help manage symptoms. In cases of chronic illness, a doctor may prescribe antiviral medication, and they will monitor the liver regularly to check for damage over time. A person should also avoid alcohol during treatment and recovery.
Hepatitis C: In most cases, hepatitis C is now considered curable, so it’s important to seek treatment early if you think you may have the virus. Current antiviral drugs that help cure hepatitis C may also help prevent the health complications of chronic liver damage.
It is important to note that there are other types of hepatitis: Hep D and Hep E. Hepatitis D is transmitted through contaminated blood and Hepatitis E transmitted through unclean water or surfaces, however, they are both treatable.
Current guidance in the UK, and many other parts of the world, ask us to stay away from other people as much as possible. This means that in-person casual sex hook-ups are discouraged.
Some of us who use PrEP are deciding to take a break from using it for the time being, if we’re not planning to have sex. If you’re thinking of stopping PrEP for a while, see the tips below. And then read the ones for starting again, so you’re prepared!
Since 2015 PrEP has become one of the most demanded HIV preventive measures because of its outstanding effectiveness rate higher than 99%. When people started taking PrEP the only regimen recommended was the daily dose, until last year when the WHO confirmed the effectiveness of this drug taken on an event base. Recently, a clinical trial on cabotegravir injections has been a breakthrough in HIV prevention, as it has shown to be 69% more effective than PrEP when injected every 8 weeks. However, the effectiveness of this drug is believed to be higher than PrEP because of its easier adherence compared to the daily dose or event based regimen of the pills. Also, the effectiveness of this drug has been only proved in cis gender men who has sex with men (MSM) and transgender women. We still don’t know if cabotegravir injections are as effective for cis gender women, but there’s currently an on-going a clinical trial to test its potential.
Doctor Will Nutland, co-founder PrEPster has told M-coalition “The new and emerging data on injectable PrEP from study HPTN 083 moves us towards having an additional PrEP option, for those people who do not find oral PrEP acceptable. Results from the companion study, HTPN 084, trialling injectable PrEP in women will cause further excitement when they are released, possibly later this year. Take-up of oral PrEP has been lower in women than in gay men, and it’s speculated that injectable PrEP might be offered to some women, if the results are as promising as HPTN 084, alongside long-acting contraception. For gay men, injectable PrEP will offer a further option – in addition to daily and event-based oral PrEP. Every option will have pros and cons for individuals – but the new data offers a further option that will be additionally attractive to many people.”
The more our prevention options are expanding the more we can contain the HIV epidemic. Cabotegravir injections have the capacity to protect key populations around the world especially the most affect communities from HIV. It can potentially solve a lot of complications of other preventative measures e.g: a condom breaking or difficulty in committing to PrEP regimen. It will also be an added value for all current HIV interventions to support them in reducing transmission and provide further preventive alternatives for their beneficiaries.
Doctor Ioannis Hodges-Mameletzis PrEP science pioneer and friend of M-Coalition “We have to now look at the data carefully before we proceed towards regulatory approval and making formal recommendations; and of course, we await with much anticipation the outcome of HPTN 084, the study looking at CAB-LA in women. We need to make sure that as we respond to COVID-19 in the midst of this pandemic, that we do not forget about the unmet needs of HIV prevention methods for our communities”
UNAIDS welcomes new tool for HIV prevention for gay men and other men who have sex with men and transgender women. (2020, May). Retrieved from https://www.unaids.org/en/resources/presscentre/pressreleaseandstatementarchive/2020/may/20200519_injectable-cabotegravir
Global HIV prevention study to stop early after ViiV Healthcare’s long-acting injectable formulation of cabotegravir dosed every two months shows higher efficacy than daily oral PrEP. (2020, May 18). Retrieved from https://viivhealthcare.com/en-gb/media/press-releases/2020/may/global-hiv-prevention-study-to-stop-early-after-viiv-healthcares/
Benjamin, R. (2020, May 18). Long-Acting Injectable PrEP Proves as Effective as Truvada. Retrieved from https://www.poz.com/article/longacting-injectable-prep-proves-even-effective-daily-truvada
MCO-AFE is launching the call to receive marketing bids for its leading project SANADI.
The M-Coalition (MCO) is the only regional network devoted to promote and support LGBTIQ health in the Middle East and North Africa Region (MENA). MCO was founded in 2014 and works through advocacy, information exchange, knowledge production, networking, and capacity building. The M-Coalition strives to involve members of the LGBTQ community and people living with HIV and other Key Populations at all levels of its strategy, policy development and implementation, and internal governing processes. M-Coalition is currently the health department of the Arab Foundation for Freedoms and Equality.
The Arab Foundation for Freedoms and Equality (AFE) is a regional organization based in MENA which encourages and supports sexual health, sexuality, gender and bodily rights movements in the Middle East and North Africa through capacity building, knowledge production, protection and advocacy.
Sanadi 2.0 is a complex activity which puts together different aspects of service delivery, knowledge, networking and emergency preparedness. By working together with professionals and different partners in MENA and beyond we are able to improve service delivery, specifically for key populations and to equip activists with tools and knowledge to better respond to emergencies and unconventional situations.
We are looking for individuals who thrive on learning experiences and communication to take on new positions for SANADI 2.0!
In these challenging times, we are presented with an opportunity to continuously strengthen community cohesion and our collective responsibility towards society. We have witnessed the importance of one another, particularly due to the disparity in governmental support. In the MENA region, we see this even more concerning health and the LGBTQIA+ community. The new pandemic has shown the vulnerability of our health systems and that of our standard civil society programming.
SANADI- which translates to “my support”- is a project aimed at facilitating communication and access to HIV and sexual health services around the MENA region. Launching in 2016, it highlighted the vital importance of preserving and facilitating the access for LGBTQ+ individual
s to health services. Due to the success of SANADI, M-Coalition and AFE have decided to expand it into an even bigger platform that enables the community to have more reach, services, and upgrades through an even friendlier user portal.
SANADI 2.0 will add precision and efficiency, focusing on bettering services by strengthening the skills of the people behind the latter.
MCO-AFE is offering a multitude of work avenues, ranging from national positions, to regional and global. We are looking for people who consider themselves active advocates for innovative change in the world. People who consider social change an act of giving back rather than an act of giving, and who thrive in collaboration and exchanging knowledge and experience.
If you fit in these attributes, please check out these links:
To apply, please click on the below link and fill your information:
ChemSex, the recreational use of drugs for sexual purposes, has been identified as an emerging trend that is lately gaining attention in the Middle East and North Africa (MENA) region. Although first observed among MSM (Men who have Sex with Men), there are signs of ChemSex engagement among other populations. However, this practice remains most popular among gay men, transwomen, and trans-MSM.